In 2019, brexanolone was launched by Sage Therapeutics as Zulresso, a novel therapy for postpartum despair. The oral model of this novel antidepressant – SAGE 217 or zuranolone – is now ending up its Section three trials.
Like brexanolone, SAGE-217 is a neurosteroid, an analogue of allopregnanolone which is a optimistic allosteric modulator of the GABA-A receptor. What distinguishes SAGE-217 from brexanolone is that it has significantly better oral bioavailability and thus doesn’t need to be administered intravenously. It may be taken as an oral remedy, similar to standard antidepressants.
On the Middle for Girls’s Psychological Well being at MGH, we are actually enrolling sufferers for the SKYLARK STUDY evaluating the efficacy and security of this remedy in new moms with extreme postpartum despair.
For data, please e mail Katherine or Miranda at [email protected] or name (617) 334-5059